Strength training and ACE I/D genotype in patients with chronic obstructive pulmonary disease (REACT III)
Long Name:Strength training and ACE I/D genotype in patients with chronic obstructive pulmonary disease (REACT III)
The goal of this pilot is to obtain variance and effect size estimates for power calculations in support of a fully powered, randomized clinical trial to examine the effect of ACE genotype on the responses to both endurance and strength training in COPD patients. Additionally, the proposed pilot will provide important information regarding the physiological mechanisms underlying the changes in physical function following strength training in COPD patients. The primary aim is to evaluate the feasibility of a 4-month strength training intervention, adherence to the intervention, drop-out from the study and variability in the change in muscle strength measurements among COPD patients recruited by ACE I/D genotype (n=15 II and n=15 DD genotypes). In addition, the effects of the intervention in both genotype groups on secondary outcomes, including physical function, quadriceps muscle and fat volumes (via computed tomography), body composition (via DXA), skeletal muscle morphology (muscle fiber cross sectional area and fiber type via muscle biopsy), and ACE-mRNA in skeletal muscle will be assessed.